TACR1 and colorectal carcinoma: These novel mechanistic findings revealed the downstream molecular events targeting the NK‐1R‐mediated GPCR signaling in human CRC and will facilitate the rational design of clinical trials to test the application of NK‐1R antagonists for the treatment of CRC, especially for the treatment of CRC with chemotherapy resistance.